Background: Trends in estimates of US pediatric SARS-CoV-2 infection-induced seroprevalence from commercial laboratory specimens may overrepresent children with frequent health care needs. We examined seroprevalence trends and compared seroprevalence estimates by testing type and diagnostic coding. Methods: Cross-sectional convenience samples of residual sera September 2021-February 2022 from 52 US jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies; monthly seroprevalence estimates were calculated by age group. Multivariate logistic analyses compared seroprevalence estimates for specimens associated with International Classification of Diseases-Tenth Revision (ICD-10) codes and laboratory orders indicating well-child care with estimates for other pediatric specimens. Results: Infection-induced SARS-CoV-2 seroprevalence increased in each age group, from 30% to 68% (1–4 years), 38% to 77% (5–11 years), and 40% to 74% (12–17 years). On multivariate analysis, patients with well-child ICD-10 codes were seropositive more often than other patients aged 1–17 years (adjusted prevalence ratio [aPR] 1.04; 95% confidence interval [CI], 1.02–1.07); children aged 9–11 years receiving standard lipid screening were seropositive more often than those receiving other laboratory tests (aPR, 1.05; 95% CI, 1.02–1.08). Conclusions: Infection-induced seroprevalence more than doubled among children younger than 12 years between September 2021 and February 2022, and increased 85% in adolescents. Differences in seroprevalence by care type did not substantially impact US pediatric seroprevalence estimates.
Background: Systemic inequities may place people with disabilities at higher risk of severe coronavirus disease 2019 (COVID-19) illness or lower likelihood to be discharged home after hospitalization. We examined whether severity of COVID-19 hospitalization outcomes and disposition differ by disability status and disability type.Methods: In a retrospective analysis of April 2020–November 2021 hospital-based administrative data among 745 375 people hospitalized with COVID-19 from 866 US hospitals, people with disabilities (n = 120 360) were identified via ICD-10-CM codes. Outcomes compared by disability status included intensive care admission, invasive mechanical ventilation (IMV), in-hospital mortality, 30-day readmission, length of stay, and disposition (discharge to home, long-term care facility (LTCF), or skilled nursing facility (SNF).Results: People with disabilities had increased risks of IMV (adjusted risk ratio [aRR]: 1.05; 95% confidence interval [CI]: 1.03–1.08) and in-hospital mortality (1.04; 1.02–1.06) compared to those with no disability; risks were higher among people with intellectual and developmental disabilities (IDD) (IMV [1.34; 1.28–1.40], mortality [1.31; 1.26–1.37]), or mobility disabilities (IMV [1.13; 1.09–1.16], mortality [1.04; 1.01–1.07]). Risk of readmission was increased among people with any disability (1.23; 1.20–1.27) and each disability type. Risks of discharge to a LTCF (1.45, 1.39–1.51) or SNF (1.78, 1.74–1.81) were increased among community-dwelling people with each disability type.Conclusions: Severity of COVID-19 hospitalization outcomes vary by disability status and type; IDD and mobility disabilities were associated with higher risks of severe outcomes. Disparities such as differences in discharge disposition by disability status require further study, which would be facilitated by standardized data on disability. Increased readmission across disability types indicates a need to improve discharge planning and support services.
1 September 2019 in International Journal of Medical Informatics
Background: Understanding the risk of hospitalization from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can guide effective public health interventions and severity assessments. This study calculated infection–hospitalization ratios (IHRs) and infection–case ratios (ICRs) to understand the relationship between SARS-CoV-2 infections, cases, and hospitalizations among different age groups during periods of Delta and Omicron variant predominance. Methods: After calculating antinucleocapsid SARS-CoV-2 antibody seroprevalence using residual commercial laboratory serum specimens, 2 ratios were computed: (1) IHRs using coronavirus disease 2019 hospitalization data and (2) ICRs using Centers for Disease Control and Prevention surveillance data. Ratios were calculated across age groups (0–17, 18–49, 50–69, and ≥70 years) for 2 time periods (September–December 2021 [Delta] and December 2021–February 2022 [Omicron]). Results: Pediatric IHRs increased from 76.7 during Delta to 258.4 during Omicron. Adult IHRs ranged from 3.0 (≥70 years) to 21.6 (18–49 years) during Delta and from 10.0 (≥70 years) to 119.1 (18–49 years) during Omicron. The pediatric ICR was lower during the Delta period (2.7) compared with the Omicron period (3.7). Adult ICRs (Delta: 1.1 [18–49 years] to 2.1 [70+ years]; Omicron: 2.2 [>70+ years] to 2.9 [50–69 years]) were lower than pediatric ICRs during both time periods. Conclusions: All age groups exhibited a lower proportion of infections associated with hospitalization in the Omicron period than the Delta period; the proportion of infections associated with hospitalization increased with each older age group. A lower proportion of SARS-CoV-2 infections were associated with reported cases in the Omicron period than in the Delta period among all age groups.